Clinical Trial Update: Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating two multiple-dose regimens of BIA 3-202 on the pharmacokinetics and motor response to Levodopa, and on erythrocyte COMT activity…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 3-202
• levodopa (levodopa)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Parkinson's Disease (PD) | Phase 2 | Status: COMPLETED